Scientific article
French

Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose

Published in

Revue médicale suisse, vol. 7, no. 299, p. 1299-1304

Publication date

2011

Abstract

Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.

Keywords

  • Bone Density/drug effects
  • Depression/drug therapy
  • Evidence-Based Medicine
  • Humans
  • Osteoporosis/chemically induced/prevention & control
  • Risk Factors
  • Serotonin Uptake Inhibitors/administration & dosage/adverse effects

UNIGE research groups

Citation (ISO format)

FÉTIQUE-WILL, Anne-Catherine, CHEVALLEY, Thierry, RIZZOLI, René. Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose. In: Revue médicale suisse, 2011, vol. 7, n° 299, p. 1299–1304.

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

http://rms.medhyg.ch/numero-299-page-1299.htm

Journal ISSN

1660-9379
751views
1downloads

Technical informations

Creation

20/12/2013 09:52:00

First validation

20/12/2013 09:52:00

Update

14/03/2023 20:47:02

Status update

14/03/2023 20:47:02

Last indexation

30/10/2024 15:36:39
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated